Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6266257rdf:typepubmed:Citationlld:pubmed
pubmed-article:6266257lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:6266257lifeskim:mentionsumls-concept:C0012155lld:lifeskim
pubmed-article:6266257lifeskim:mentionsumls-concept:C0029442lld:lifeskim
pubmed-article:6266257lifeskim:mentionsumls-concept:C0006674lld:lifeskim
pubmed-article:6266257lifeskim:mentionsumls-concept:C0008318lld:lifeskim
pubmed-article:6266257lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6266257lifeskim:mentionsumls-concept:C0204695lld:lifeskim
pubmed-article:6266257lifeskim:mentionsumls-concept:C0205251lld:lifeskim
pubmed-article:6266257pubmed:issue1lld:pubmed
pubmed-article:6266257pubmed:dateCreated1981-9-15lld:pubmed
pubmed-article:6266257pubmed:abstractTextThe objectives of this study were to evaluate the effects of vitamin D(3) (D(3)) and 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) on uremic bone disease independent of their action on the intestine. The histomorphology of tibial metaphyses in uremic (5/6 nephrectomized [5/6 Nx]) rats fed a low-calcium-low-phosphorus (LCLP) diet was compared with sham-operated (SO) rats fed an LCLP diet and 5/6 Nx rats fed an LCLP diet and given 15,000 IU D(3) or 5 units (135 ng) 1,25-(OH)(2)D(3) daily for 7 days. A marked osteomalacia characterized by an increased percentage of active and inactive trabecular osteoid surface and thickened growth plates developed in proximal tibial metaphyses in 5/6 Nx rats given the placebo, compared with SO rats. These bone changes were associated with relative hypophosphatemia, hypophosphaturia, and hypercalciuria in 5/6 Nx rats. In 5/6 Nx rats treated with D(3) or 1,25-(OH)(2)D(3) the growth plates had undergone mineralization and vascular invasion and were markedly reduced in thickness. Other parameters of osteomalacia in trabecular bone were not different from 5/6 Nx rats given the placebo. There was a significant decrease in osteoclasts per millimeter of trabecular surface perimeter in D(3)- and 1,25-(OH)(2)D(3)-treated rats. These bone changes were associated with hypercalcemia, hyperphosphatemia, and hyperphosphaturia, compared with 5/6 Nx rats given the placebo. It was concluded that in uremic rats fed the LCLP diet, shortterm treatment with either pharmacologic levels of D(3) or 1,25-(OH)(2)D(3) corrected only lesions in the growth plate. Osteoid seams were not reduced in treated rats, although the serum calcium-phosphorus product was elevated. The 5/6 Nx rat fed the LCLP diet appears to be a useful model for the rapid induction of uremic osteomalacia in adult animals.lld:pubmed
pubmed-article:6266257pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:languageenglld:pubmed
pubmed-article:6266257pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6266257pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6266257pubmed:statusMEDLINElld:pubmed
pubmed-article:6266257pubmed:monthJullld:pubmed
pubmed-article:6266257pubmed:issn0002-9440lld:pubmed
pubmed-article:6266257pubmed:authorpubmed-author:WeisbrodeS...lld:pubmed
pubmed-article:6266257pubmed:issnTypePrintlld:pubmed
pubmed-article:6266257pubmed:volume104lld:pubmed
pubmed-article:6266257pubmed:ownerNLMlld:pubmed
pubmed-article:6266257pubmed:authorsCompleteYlld:pubmed
pubmed-article:6266257pubmed:pagination35-40lld:pubmed
pubmed-article:6266257pubmed:dateRevised2010-9-10lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:meshHeadingpubmed-meshheading:6266257-...lld:pubmed
pubmed-article:6266257pubmed:year1981lld:pubmed
pubmed-article:6266257pubmed:articleTitleShort-term effects of vitamin D3 and 1,25-dihydroxyvitamin D3 on osteomalacia in uremic rats fed a low calcium-low-phosphorus diet.lld:pubmed
pubmed-article:6266257pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6266257pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed